☆ 4.7 Article

A Pilot Study for the Evaluation of an Interferon Gamma Release Assay (IGRA) To Measure T-Cell Immune Responses after SARS-CoV-2 Infection or Vaccination in a Unique Cloistered Cohort

JOURNAL OF CLINICAL MICROBIOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Surgery

Negative immune responses to two-dose mRNA COVID-19 vaccines in renal allograft recipients assessed with simple antibody and interferon gamma release assay cellular monitoring

Marta Crespo et al.

Summary: Studies have shown that kidney transplant recipients have lower immune responses to mRNA coronavirus vaccines, especially in those recently transplanted. Simple humoral and cellular monitoring is recommended to determine the need for repeated doses. Overall, a significant portion of healthy controls, dialysis patients, and kidney transplant recipients developed some form of immune response to SARS-CoV-2.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

添加到收藏夹

Article Immunology

Interferon-γ Release Assay for Accurate Detection of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Response

Kanagavel Murugesan et al.

Summary: The study found that the interferon-gamma release assay (IGRA) accurately distinguished between convalescent and uninfected healthy blood donors, with a predominantly CD4(+) T-cell response. Therefore, SARS-CoV-2 IGRA may serve as a useful diagnostic tool in managing the coronavirus disease 2019 pandemic.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients

Linda Petrone et al.

Summary: The study showed that specific T cell responses to SARS CoV 2 peptides can be detected in COVID-19 patients and are significantly different from individuals without COVID-19. This immune response exhibits characteristics of both Th1 and Th2 profiles, potentially serving as a new T cell-based diagnostic tool.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

COVID-19-neutralizing antibodies predict disease severity and survival

Wilfredo F. Garcia-Beltran et al.

Summary: Severe cases of COVID-19 show increased inflammatory markers, lymphopenia, pro-inflammatory cytokines, and high antibody levels. High neutralization potency is a predictor of survival. Patient sera can neutralize different strains, indicating cross-protection from reinfection.

CELL (2021)

添加到收藏夹

Review Immunology

Reinfection With SARS-CoV-2: Implications for Vaccines

Jeffrey Cohen et al.

Summary: The likelihood and duration of reinfection with SARS-CoV-2 remain uncertain, as current knowledge on this topic is limited. Studies on other respiratory viruses suggest that serum antibodies typically persist for only a few months to a few years, making reinfections common. These findings have implications for vaccine development and the need for continued protective measures.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Immunology

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

Alexandra Schafer et al.

Summary: The study shows that combined use of hu-mAbs is effective for prevention and therapy of SARS-CoV-2 infection, but in vivo protection is influenced by intact effector function.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

添加到收藏夹

Article Virology

Evaluation of seven commercial RT-PCR kits for COVID-19 testing in pooled clinical specimens

Atul Garg et al.

Summary: This study compared and evaluated seven commercially available COVID-19 RT-PCR kits for pooled sample testing, finding that TRUPCR, TaqPath, Allplex, and BGI kits showed 100% sensitivity, specificity, and accuracy for weakly positive pooled samples.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Correlates of protection against SARS-CoV-2 in rhesus macaques

Katherine McMahan et al.

Summary: Adoptive transfer of purified IgG from convalescent macaques protects naive macaques against SARS-CoV-2 infection, and cellular immune responses contribute to protection against rechallenge with SARS-CoV-2. The findings suggest that relatively low antibody titres are sufficient for protection against SARS-CoV-2 in macaques, while higher antibody titres are required for treatment of SARS-CoV-2 infection.

NATURE (2021)

添加到收藏夹

Review Multidisciplinary Sciences

T cell response to SARS-CoV-2 infection in humans: A systematic review

Madhumita Shrotri et al.

Summary: The study found that COVID-19 patients exhibit T cell lymphopenia, which is positively correlated with disease severity, duration of RNA positivity, and non-survival. Those with severe or critical disease tend to develop more robust, virus-specific T cell responses. Cross-reactive T cell responses have been demonstrated in unexposed and uninfected adults, but their significance for protection and susceptibility remains unclear.

PLOS ONE (2021)

添加到收藏夹

Article Medicine, General & Internal

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

Kathryn E. Stephenson et al.

Summary: The study evaluated the immunogenicity of the Ad26.COV2.S vaccine in human participants, showing rapid induction of spike-specific humoral and cellular immune responses. Various antibody subclasses, Fc receptor binding properties, and antiviral functions were induced, along with CD4+ and CD8+ T-cell responses.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Anil Gupta et al.

Summary: In this study, among nonhospitalized patients with symptomatic Covid-19, sotrovimab treatment significantly reduced the risk of disease progression leading to hospitalization or death compared to placebo. Patients receiving sotrovimab also had a lower rate of serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

Rishi R. Goel et al.

Summary: This study found that immune memory to SARS-CoV-2 and its variants remains robust for at least 6 months after mRNA vaccination, with antibodies declining but still detectable in most individuals. mRNA vaccines also induced functional memory B cells and antigen-specific T cells, with recall responses primarily increasing antibody levels in individuals with preexisting immunity.

SCIENCE (2021)

添加到收藏夹

Letter Immunology

Humoral and Cellular Immunogenicity of the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Nursing Home Residents

Jens T. Van Praet et al.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients

Alessandra Aiello et al.

Summary: The whole-blood platform was used to detect a SARS-CoV-2-specific T cell response, with pool S and MegaPool being the most potent immunogenic stimuli. The assay showed good sensitivity and high specificity, making it a powerful diagnostic tool for clinical laboratories.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Pre-existing T-cell immunity to SARS-CoV-2 in unexposed healthy controls in Ecuador, as detected with a COVID-19 Interferon-Gamma Release Assay

Gustavo Echeverria et al.

Summary: The study conducted in Ecuador found that a portion of unexposed healthy individuals may have pre-existing T-cell immunity to SARS-CoV-2, likely due to previous exposure to other coronaviruses or microbial antigens. This suggests that a part of the population may have pre-existing immune responses to the virus, even without prior exposure.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach

Alessandra D'Abramo et al.

Summary: Prolonged B-cell depletion caused by anti-CD20 therapy impairs the adaptive immune response, leading to severe manifestations during COVID-19. Two patients under anti-CD20 therapy experienced prolonged and severe COVID-19 but were successfully treated with mAbs targeting the SARS-CoV-2 spike proteins.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Immunogenic T cell epitopes of SARS-CoV-2 are recognized by circulating memory and naive CD8 T cells of unexposed individuals

Isaac Quiros-Fernandez et al.

Summary: Recent studies have shown evidence of cross-reactive CD8 T cells in non-exposed individuals to SARS-CoV-2, which can stabilize HLA molecules and activate CD8 T cells in healthy unexposed subjects. The reactive cells were found in naive, memory, and effector subsets, indicating a diverse T cell response in individuals without previous exposure to the virus.

EBIOMEDICINE (2021)

添加到收藏夹

Article Immunology

Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay

Isabel Brand et al.

Summary: Adaptive immune responses to structural proteins of the SARS-CoV-2 virus play a crucial role in protection against COVID-19. This study found that convalescent COVID-19 patients still exhibit broad T cell reactivity to multiple SARS-CoV-2 structural proteins over 200 days after infection. The study also showed a loose but significant correlation between anti-Nucleocapsid antibody titer and the magnitude and breadth of the T cell response.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Review Infectious Diseases

The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses

Delia Goletti et al.

Summary: T-cell responses play a crucial role in COVID-19, providing early detection of disease progression and predictive value for severity and survival rates. Vaccination stimulates robust T-cell responses, contributing significantly to protective immunity, although understanding of long-term T-cell responses remains limited.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

添加到收藏夹

Letter Infectious Diseases

Negative SARS-CoV-2 antibodies, T-cell response and virus neutralization following full vaccination in a renal transplant recipient: a call for vigilance

Rune M. Pedersen et al.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

添加到收藏夹

Letter Medicine, General & Internal

Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses

Ilies Benotmane et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia et al.

Summary: To date, there are no immunological data on COVID-19 heterologous vaccination schedules in humans. This study evaluated the immunogenicity and reactogenicity of administering BNT162b2 as a second dose in individuals primed with ChAdOx1-S. The results showed that BNT162b2 induced a robust immune response in individuals prime vaccinated with ChAdOx1-S, with an acceptable and manageable reactogenicity profile.

LANCET (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021

Catherine M. Brown et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

添加到收藏夹

Article Immunology

SARS-CoV-2 variants of concern partially escape humoral but not T- cell responses in COVID-19 convalescent donors and vaccinees

Daryl Geers et al.

Summary: This study suggests that some variants might partially escape humoral immunity induced by SARS-CoV-2 infection or BNT162b2 vaccination, but the S-specific CD4(+) T-cell activation is not affected by the mutations in the B.1.1.7 and B.1.351 variants.

SCIENCE IMMUNOLOGY (2021)

添加到收藏夹

Article Infectious Diseases

Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently Vaccinated Individuals

Soumya Jaganathan et al.

Summary: This study evaluated total antibody and T cell responses in COVID-19 convalescents and vaccinated individuals, finding robust immune responses to SARS-CoV-2 mRNA vaccines in vaccinated subjects and sustained responses in convalescent donors for up to 1 year post-infection.

INFECTIOUS DISEASES AND THERAPY (2021)

添加到收藏夹

Article Cell Biology

Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals

Alison Tarke et al.

Summary: The study showed that SARS-CoV-2 variants do not significantly disrupt total T cell reactivity, although decreases in response frequency of 10%-22% were observed under certain assay/VOC combinations. This underscores the importance of actively monitoring T cell responses in the context of SARS-CoV-2 evolution.

CELL REPORTS MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

After the pandemic: perspectives on the future trajectory of COVID-19

Amalio Telenti et al.

Summary: This article discusses the future patterns of SARS-CoV-2 infection, the development of variants, and the implications for vaccine deployment. It suggests that the virus may become endemic fueled by pockets of susceptible individuals and waning immunity. Effective surveillance and response are crucial to prevent new epidemic or pandemic patterns.

NATURE (2021)

添加到收藏夹

Article Immunology

Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France

Floriane Gallais et al.

Summary: The study found that all confirmed COVID-19 patients had SARS-CoV-2 specific antibodies and T-cell responses lasting up to 102 days after symptom onset, while their contacts remained seronegative but 6 of them reported COVID-19 symptoms within a median of 7 days and 4 of them had positive SARS-CoV-2 specific T-cell responses lasting up to 93 days after infection.

EMERGING INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Allergy

A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia

Isabella Quinti et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

添加到收藏夹

Article Allergy

Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover

Annarosa Soresina et al.

PEDIATRIC ALLERGY AND IMMUNOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Nina Le Bert et al.

NATURE (2020)

添加到收藏夹

Editorial Material Medicine, General & Internal

COVID-19 and the Path to Immunity

David S. Stephens et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Microbiology

Recommendations for use of antigenic tests in the diagnosis of acute SARS-CoV-2 infection in the second pandemic wave: attitude in different clinical settings

Francisco Javier Candel et al.

REVISTA ESPANOLA DE QUIMIOTERAPIA (2020)

添加到收藏夹

Editorial Material Immunology

An Effective COVID-19 Vaccine Needs to Engage T Cells

Karsten Sauer et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Virology

Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect

Gabriel N. Maine et al.

JOURNAL OF CLINICAL VIROLOGY (2020)

添加到收藏夹

Review Immunology

What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?

Marc Hellerstein

VACCINE: X (2020)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.